Stock 300558 BETTA PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Betta Pharmaceuticals Co., Ltd. Stock

Equities

300558

CNE100002DD9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-14 pm EDT 		5-day change 1st Jan Change
37.61 CNY -0.97% Intraday chart for Betta Pharmaceuticals Co., Ltd. -3.56% -27.04%
Jan. 04 C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI
2023 Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Financials

Sales 2023 * 2.64B 365M Sales 2024 * 3.47B 479M Capitalization 15.74B 2.17B
Net income 2023 * 318M 43.94M Net income 2024 * 498M 68.81M EV / Sales 2023 * 6.43 x
Net Debt 2023 * 1.24B 172M Net Debt 2024 * 1.29B 178M EV / Sales 2024 * 4.91 x
P/E ratio 2023 *
49.5 x
P/E ratio 2024 *
31.5 x
Employees 1,961
Yield 2023 *
0.38%
Yield 2024 *
0.56%
Free-Float 51.55%
More Fundamentals * Assessed data

Chart Betta Pharmaceuticals Co., Ltd.

Dynamic Chart

Latest news about Betta Pharmaceuticals Co., Ltd.

C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd. CI
C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance DJ
Betta Pharmaceuticals Gets Nod for Voronib Tablets' Listing MT
Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023 CI
C4 Therapeutics, Betta Pharmaceuticals Sign Deal to Develop, Commercialize CFT8919 in Greater China MT
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC CI
C4 Therapeutics, Inc. announced that it expects to receive $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI
Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022 CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Betta Pharmaceuticals Co., Ltd. Announces Profit Distribution Proposal for 2022 CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Betta Pharmaceuticals Gets Nod to Start Clinical Trial of Tumor Drug in China MT
More news

Quotes and Performance

1 day-2.54%
1 week-5.59%
Current month-7.18%
1 month-19.09%
3 months-18.59%
6 months-37.54%
Current year-26.32%
More quotes

Highs and lows

1 week
37.96
Extreme 37.96
40.03
1 month
37.96
Extreme 37.96
47.52
Current year
33.11
Extreme 33.11
52.33
1 year
33.11
Extreme 33.11
73.11
3 years
33.11
Extreme 33.11
122.00
5 years
33.11
Extreme 33.11
160.66
10 years
23.19
Extreme 23.19
160.66
More quotes

Managers and Directors - Betta Pharmaceuticals Co., Ltd.

Managers TitleAgeSince
Jia Tong CEO
 Chief Executive Officer 46 02-12-31
Lie Ming Ding CEO
 Chief Executive Officer 60 03-01-06
Jian Xun Fan DFI
 Director of Finance/CFO 53 15-12-31
Members of the board TitleAgeSince
Lie Ming Ding CEO
 Chief Executive Officer 60 03-01-06
Wei Wang BRD
 Director/Board Member 57 19-11-21
Jia Tong CEO
 Chief Executive Officer 46 02-12-31
More insiders

ETFs positioned on Betta Pharmaceuticals Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
0.36% 2 M€ -19.24% -
More ETFs positioned on Betta Pharmaceuticals Co., Ltd.

Quotes

Date Price Change Volume
24-04-15 37.61 -0.97% 5,830,185
24-04-12 37.98 -2.54% 3,559,491
24-04-11 38.97 -0.43% 3,171,805
24-04-10 39.14 -2.13% 2,859,795
24-04-09 39.99 +2.54% 3,706,819

End-of-day quote Shenzhen S.E., April 11, 2024

More quotes

Company Profile

Betta Pharmaceuticals Co Ltd is a company mainly engaged in research, development, production and sales of innovative drugs for the treatment of malignant tumors. The Company's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The Company is also engaged in promotional services, real estate leasing and other businesses.
Sector
Pharmaceuticals
Calendar
2024-04-19 - Q4 2023 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Betta Pharmaceuticals Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
37.61 CNY
Average target price
57.03 CNY
Spread / Average Target
+51.64%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-26.32% 2.2B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.64% 9.37B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.73% 4.9B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+22.86% 3.86B
YUHAN CORPORATION Stock Yuhan Corporation
+1.45% 3.83B
INDIVIOR PLC Stock Indivior PLC
+32.57% 2.64B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-24.17% 2.31B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+4.35% 1.66B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
-3.78% 1.59B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300558 Stock